Prostate cancer immunotherapy: Choices for patients and clinicians

Oncology Spectrums

Volumn 2, Issue 7, 2001, Pages 462-468

  Salgaller, M L ^a  

^a Northwest Biotherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA INTERFERON; ANTIANDROGEN; BICALUTAMIDE; CANCER VACCINE; CAPROMAB PENDETIDE IN 111; DNA; ESTRAMUSTINE; ESTROGEN; FLUOROURACIL; FLUTAMIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; IODINE 131; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49; NILUTAMIDE; PA 2024; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RECOMBINANT PROTEIN; RETINOIC ACID; RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; IN VIVO STUDY; LEUKOPENIA; MALAISE; MALE; MULTICENTER STUDY; NEUROTOXICITY; NONHUMAN; ORCHIECTOMY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RAT; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR IMMUNITY; WEIGHT REDUCTION;

EID: 0034866824     PISSN: 15328554     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Progress in active specific immunotherapy of prostate cancer
2. Screening and early hormonal treatment of prostate cancer are accumulating strong evidence ans support
3. The lifetime risk of developing prostate cancer in white and black men
4. Clinical trials in relapsed prostate cancer: Defining the target
5. Response criteria in prostatic carcinoma
6. Introduction: A therapeutically relevant framework for the classification of human prostate cancer
7. A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour
8. Response criteria for the prostate of the USA National Prostatic Cancer Project
9. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray extrnal beam irradiation in the treatment of patients with clinically localized, low to high prostate carcinoma
10. Importance of continued testicular suppression in hormone-refractory prostate cancer
11. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome
12. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
13. Parenteral polyoestradiol phosphate vs orchiectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: A 2-year follow-up report of a national, prospective prostatic cancer study
14. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer
15. High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate
16. Tamoxifen in advanced prostate cancer: An ECOG pilot study
17. Treatment of metastatic prostate cancer. Lessons from the androgen receptor
18. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions
19. One hundred thirteen men with hormone-refractory prostate cancer died today
20. Management of hormone refractory prostate cancer: Current standards and future prospects
21. Approaches to the treatment of patients wit hormone-sensitive prostate cancer
22. Immunological surveillance in neoplasia
23. Immunological aspects of malignant disease
24. Tumor vaccine design: Concepts, mechanisms, and efficacy testing
25. Tumor immunology: An overview
26. Tumor immunology
27. Cancer vaccines
28. Human tumor antigens recognized by T lymphocytes
29. Capture and processing of exogenous antigens for presentations on MHC molecules
30. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bactrial products
31. Tumour surveillance: Missing peptides and MHC molecules
32. HLA class I antigen downregulation in human cancers: T-cells immunotherapy revives and old story
33. Regulation of dendritic cell system by tumor
34. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo
35. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
36. Molecular ccloning of a complementary DNA encoding a prostate-specific membrane antigen
37. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases
38. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases
39. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy
40. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
41. Dendritic cell-based immunotheraphy of prostate cancer: Immune monitoring of a phase II clinical trial
42. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
43. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
44. Follow-up evaluation of a phase II prostate cancer vaccine trial
45. Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials
46. rPSMA-loaded autologous dendritic cell vaccine (CaPVax) safely activates cellular and humoral responses against androgen-endependent prostate cancer
47. Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells
48. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
49. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
50. Prostate cancer vaccines: Current status
51. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA)
52. Immunohistochemical and pharmacokinetic characterization of the site-epecific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5
53. PROSTASCINT scan for staging prostate cancer
54. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer
55. PSMA specific antibodies and their diagnosis and therapeutic use
56. Prostate-specific membrane antigen is produced in tumor-associated neovasculature
57. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49
58. Interferon-gamma and monoclonal antibody 131I-labeled CC49: Outcomes in patients with androgen-independent prostate cancer
59. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer
60. Gene therapy for protate cancer
61. Immunological approaches for the treatment of prostate cancer
62. Adenovirus-mediated transfer of inducible caspases: A novel "death switch" gene therapeutic approach to prostate cancer
63. Aldenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer
64. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice
65. Targeting therapeutic gene expression to human prostate cancers
66. Gene therapy for prostate cancer
67. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology
68. Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer
69. Immunotherapy of prostate cancer in the dunning rat model: Use of cytokine gene modified tumor vaccines
70. Therapy of advanced prostate cancer with granuclocyte macrophage colony stimulating factor
71. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor gene transfer
72. Toxicities of human recombinant interferon-alpha 2 in patients with advanced prostate carcinoma
73. A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer
74. The results of a phase II randomized trial comparing 4-fluorouracil and 5-fluorouracil plus alpha-interferon: Observations on the design of clinical trials for androgen-independent prostate cancer
75. Clinical trials of immunotherapy for prostate cancer
76. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy
77. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotoopic model
78. Prostate cancer gene therapy: Comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines
79. NK cell-mediated anti-tumor immune respose to human prostate cancer cell, PC-3: Immunogene therapy using a highly secretable form of interleukin-15 gene transfer
80. Viral vector delivery in solid-state vehicles: Gene expression in a murine prostate cancer model
81. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy
82. The next generation of vaccines for the treatment of cancer
83. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines
84. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
85. Peptide and carbohydrate vaccines in relapsed prostate cancer: Immunogenicity of synthetic vaccines in man - Clinical trials at Memorial Sloan-Kettering Cancer Center
86. Heterogeneity of mucin g ene expression in normal and neoplastic ttissues
87. A potential role for activated HER-2 in prostate cancer
88. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer
89. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
90. Prostate stem cell antigen is a promising candidate for immunottherapy of advanced prostate cancer
91. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts
92. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression
93. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors
94. PART-1: A novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12
95. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
96. Identification and characterization of prostein, a novel prostate-specific proten
97. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer
98. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer
99. The immunotherapy of prostate cancer
100. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy
101. Molecular characterization of defective antigen processing in human prostate cancer
102. Failure of cancer vaccines: The significant limitations of this approach to immunotherapy
103. Living with treatment decisions: Regrets and quality of life among men treated for metastatic prostate cancer